Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin
Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin
复制标题
DOI：
10.1016/j.ijantimicag.2009.10.019
复制
发表时间：
2010-03-01
影响因子：
10.8
通讯作者：
Samonis, George
中科院分区：
文献类型：
--
作者：
Falagas, Matthew E.;Maraki, Sofia;Samonis, George
肠杆菌科之间不断提高的抗菌素耐药性使得有必要对潜在的新的治疗方案进行评估。本研究旨在评价磷霉素对多重耐药(MDR)肠杆菌科分离株的体外抗菌活性。用Etest方法检测了2007年11月至2009年4月在希腊克里特岛伊拉克利安大学医院收集的肠杆菌科耐药菌株对磷霉素和其他12种抗生素的药敏情况。共分离152株耐多药肠杆菌科细菌，包括肺炎克雷伯菌(76.3%)、大肠埃希菌(17.1%)、奇异变形杆菌(4.6%)和其他菌(2.0%)。其次为亚胺培南(35.5%)、四环素(20.4%)、庆大霉素(19.7%)、甲氧苄氨嘧啶/磺胺甲恶唑(12.5%)和环丙沙星(10.5%)。152株细菌中，85株(55.9%)对广泛耐药(XDR)，其中78株(91.8%)对磷霉素敏感。79株产碳青霉烯酶、34株产超广谱β-内酰胺酶和24株产金属β-内酰胺酶菌株对磷霉素的敏感率分别为94.9%、94.1%和83.3%。综上所述，在本研究中，磷霉素对MDR和XDR肠杆菌具有良好的体外抗菌活性。我们建议进一步评估磷霉素对这些病原体引起的感染的潜在临床效用。(C)2009年爱思唯尔公司和国际化疗学会。版权所有。
The advancing antimicrobial drug resistance among Enterobacteriaceae renders the evaluation of potential novel therapeutic options necessary. We sought to evaluate the in vitro antimicrobial activity of fosfomycin against multidrug-resistant (MDR) Enterobacteriaceae isolates. Antimicrobial susceptibility to fosfomycin and 12 additional antibiotics of MDR Enterobacteriaceae isolates collected between November 2007 and April 2009 at the University Hospital of Heraklion, Crete, Greece, was examined using the Etest method. A total of 152 MDR Enterobacteriaceae isolates were studied, including Klebsiella pneumoniae (76.3%), Escherichia coli (17.1%), Proteus mirabilis (4.6%) and other species (2.0%). Antimicrobial susceptibility rates were highest for fosfomycin (92.8%), tigecycline (92.1%) and colistin (73.0%) followed by imipenem (35.5%), tetracycline (20.4%), gentamicin (19.7%), trimethoprim/sulfamethoxazole (12.5%) and ciprofloxacin (10.5%). Of the 152 isolates, 85 (55.9%) were extensively drug-resistant (XDR), of which 78 (91.8%) remained susceptible to fosfomycin. Susceptibility to fosfomycin of the 79 carbapenemase-producing, 34 extended-spectrum beta-lactamase-producing and 24 metallo-beta-lactamase-producing isolates was 94.9%, 94.1% and 83.3%, respectively. In conclusion, in this study fosfomycin exhibited good in vitro antimicrobial activity against MDR and XDR Enterobacteriaceae. We suggest further evaluation of the potential clinical utility of fosfomycin against infections caused by these pathogens. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.